Next‐generation sequencing of oncogenes and tumor suppressor genes in odontogenic myxomas

Background Mutations previously considered drivers of malignant neoplasms also occur in benign tumors. From the biological perspective, the study of malignant and benign neoplasms is equally relevant. The study of rare tumors contributes to the understanding of the more common ones, as both could sh...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oral pathology & medicine 2017-11, Vol.46 (10), p.1036-1039
Main Authors: Santos, Jean Nunes, Sousa Neto, Ernesto Santos, França, Josiane Alves, Diniz, Marina Gonçalves, Moreira, Rennan Garcias, Castro, Wagner Henriques, Gomez, Ricardo Santiago, Sousa, Silvia Ferreira, Gomes, Carolina Cavalieri
Format: Article
Language:English
Subjects:
Adult
Benign
benign neoplasms
bone tumors
Cancer
Dentistry
DNA, Neoplasm - genetics
Female
Genes, Tumor Suppressor
genetics
Genomes
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Mutation
Myxoma
Myxoma - genetics
Odontogenic tumors
Odontogenic Tumors - genetics
Oncogenes
Oncogenes - genetics
p53 Protein
Sequence Analysis, DNA
Tumor suppressor genes
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Mutations previously considered drivers of malignant neoplasms also occur in benign tumors. From the biological perspective, the study of malignant and benign neoplasms is equally relevant. The study of rare tumors contributes to the understanding of the more common ones, as both could share the same hallmark genetic drivers. The identification of driver mutations in benign tumors is facilitated by the fact that they harbor quiet genomes. Pathogenic mutations have being described in benign epithelial odontogenic tumors, such as ameloblastomas and adenomatoid odontogenic tumors. However, the molecular pathogenesis of odontogenic myxoma (OM), a benign aggressive ectomesenchymal tumor, is still poorly characterized, precluding the development of personalized therapy. Aiming to find druggable genetic mutations, we investigated in OM mutations in 50 genes commonly mutated in cancer. Methods We used targeted next‐generation sequencing to interrogate over 2,800 COSMIC mutations in OM. Results Missense single nucleotide variants were detected in KDR, TP53, PIK3CA, KIT, JAK3; however, these did not include pathogenic mutations. Conclusion These aggressive tumors do not harbor pathogenic mutations in genes commonly mutated in human cancers or if they do, these mutations probably occur in a low proportion of cases.
ISSN:0904-2512
1600-0714
DOI:10.1111/jop.12598